Riyadh: King Faisal Specialist Hospital and Research Centre (KFSHRC) led Saudi healthcare institutions in clinical trials during the first half of 2025, conducting 48% of all clinical trials registered nationwide. The hospital recorded 104 active clinical trials and initiated 80 new studies, providing patients with broader access to innovative therapies and expanding future treatment options.
According to Saudi Press Agency, clinical trials registered in the Kingdom during the first half of 2025 focused on cancer, cardiovascular diseases, musculoskeletal, dermatological and autoimmune conditions, gastrointestinal and liver diseases, and endocrine and metabolic disorders.
Among the most notable trials announced recently, KFSHRC reported the successful treatment of the first patient using genetically engineered CAR-T cells manufactured locally, as part of a Phase I clinical trial for patients with relapsed acute lymphoblastic leukemia. This milestone represents a significant advancement in gene and cell therapies.
KFSHRC continues to strengthen its research capabilities in advanced therapies, including gene and cellular treatments, while expanding into new clinical trials that support medical innovation. These efforts reinforce its role as a pioneering healthcare institution and align with the objectives of Saudi Vision 2030.
The hospital was ranked first in the Middle East and North Africa and 15th globally among the world’s top 250 academic healthcare institutions for 2025. It was also recognized as the most valuable healthcare brand in Saudi Arabia and the Middle East by Brand Finance in 2024, and listed among the World’s Best Smart Hospitals 2025 by Newsweek.
